Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention

JAMA

Volumn 302, Issue 22, 2009, Pages 2458-2464

  Tsai, Thomas T ^a,b,c   Maddox, Thomas M ^a,b,c   Roe, Matthew T ^d   Dai, David ^d   Alexander, Karen P ^d   Ho, P Michael ^a,b,c   Messenger, John C ^b   Nallamothu, Brahmajee K ^e   Peterson, Eric D ^d   Rumsfeld, John S ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Colorado Cardiovascular Outcomes Research Group ^*  (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ENOXAPARIN; EPTIFIBATIDE; HEPARIN; HIRULOG;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLEEDING; CONTROLLED STUDY; DRUG CONTRAINDICATION; DRUG FATALITY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROPERITONEAL HEMORRHAGE; TREATMENT CONTRAINDICATION; UNITED STATES;

EID: 71549119500     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.1800     Document Type: Article

References (19)

1. Ebbesen J, Buajordet I, Erikssen J, et al. Drug-related deaths in a department of internal medicine. Arch Intern Med. 2001;161(19):2317-2323. (Pubitemid 32980130)
2. Bates DW, Cullen DJ, Laird N, et al; ADE Prevention Study Group. Incidence of adverse drug events and potential adverse drug events: implications for prevention. JAMA. 1995;274(1):29-34.
3. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol. 2002;13(suppl 1):S37-S40.
4. Anderson RJ, Melikian DM, Gambertoglio JG, et al. Prescribing medication in long-term dialysis units. Arch Intern Med. 1982;142(7):1305-1308.
5. Kaplan B, Mason NA, Shimp LA, Ascione FJ. Chronic hemodialysis patients: part I, characterization and drug-related problems. Ann Pharmacother. 1994;28(3):316-319. (Pubitemid 24105502)
6. Kaplan B, Shimp LA, Mason NA, Ascione FJ. Chronic hemodialysis patients: part II, reducing drug-related problems through application of the focused drug therapy review program. Ann Pharmacother. 1994;28(3):320-324. (Pubitemid 24105503)
7. Manley HJ, McClaran ML, Overbay DK, et al. Factors associated with medication-related problems in ambulatory hemodialysis patients. Am J Kidney Dis. 2003;41(2):386-393. (Pubitemid 36152458)
8. Busby LT, Weyman A, Rodgers GM. Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin. Am J Hematol. 2001;67(1):54-56. (Pubitemid 32336706)
9. Gerlach AT, Pickworth KK, Seth SK, Tanna SB, Barnes JF. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy. 2000;20(7):771-775.
10. Thorevska N, Amoateng-Adjepong Y, Sabahi R, et al. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest. 2004;125(3):856-863. (Pubitemid 38367274)
11. Brindis RG, Fitzgerald S, Anderson HV, Shaw RE, Weintraub WS, Williams JF. The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR): building a national clinical data repository. J Am Coll Cardiol. 2001;37(8):2240-2245. (Pubitemid 32548015)
12. Weintraub WS, McKay CR, Riner RN, et al; American College of Cardiology Database Committee. The American College of Cardiology National Database: progress and challenges. J Am Coll Cardiol. 1997;29(2):459-465.
13. Lexi-Comp Inc (Lexi-Drugs). http://www.lexi.com/. Accessed September 22, 2009.
14. Shaw RE, Anderson HV, Brindis RG, et al. Development of a risk adjustment mortality model using the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR) experience: 1998-2000. J Am Coll Cardiol. 2002;39(7):1104-1112.
15. Mehta SK, Frutkin AD, Lindsey JB, et al. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Cardiovasc Intervent. 2009;2:222-229.
16. Institute of Medicine. To Err Is Human: Building a Safer Health System. Kohn LT, Corrigan JM, Donaldson MS, eds. Washington, DC: National Academies Press; 1999.
17. Long CL, Raebel MA, Price DW, Magid DJ. Compliance with dosing guidelines in patients with chronic kidney disease. Ann Pharmacother. 2004;38(5):853-858. (Pubitemid 38509067)
18. Manley HJ, Drayer DK, Muther RS. Medication-related problem type and appearance rate in ambulatory hemodialysis patients. BMC Nephrol. 2003;4:10.
19. Gurm HS, Smith DE, Collins JS, et al; Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention. J Am Coll Cardiol. 2008;51(5):529-535.